A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade
Details
Age
Adult
Eligibility
Must have a lesion of sufficient size to support injection of complete first dose of mRNA-2752
Type of Study
Treatment
Locations
University of Colorado Hospital
Principal Investigator
Antonio Jimeno, MD, PhD
Study ID
Protocol Number: 18-1526
More information available at ClinicalTrials.gov: NCT03739931
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers